N-Succinimidyl-2-(2-pyridyldithio)-propionat | 68617-67-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-Succinimidyl-2-(2-pyridyldithio)-propionat
• 英文别名: N-succinimidyl-2-(2-pyridyldithio) propionate；(2,5-Dioxopyrrolidin-1-yl) 2-(pyridin-2-yldisulfanyl)propanoate
• CAS: 68617-67-4
• 化学式: C₁₂H₁₂N₂O₄S₂
• 分子量: 312.37
• InChiKey: AZKPTEVGTAQJDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  127
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS
  申请人：TUFTS MEDICAL CENTER

  公开号：US20160052982A1

  公开（公告）日：2016-02-25

  The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.

  本申请提供了制备可溶性脂质化配体药剂的方法，包括配体实体和脂质实体，并在某些实施例中提供了这些组分的相关参数，从而使得能够适当选择组分来组装出针对任何感兴趣的靶点的活性药剂。
• [EN] ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF<br/>[FR] DÉRIVÉS ANTICANCÉREUX, LEUR SYNTHÈSE ET LEURS APPLICATIONS THÉRAPEUTIQUES
  申请人：SANOFI SA

  公开号：WO2012014147A1

  公开（公告）日：2012-02-02

  The present invention relates to conjugales of pyrrolo[1,4]benzodiazepine (PBD) dimers, to compositions containing them and to their therapeutic use, especially as anticancer agents. The invention also relates to the process for preparing the conjugates and to their use as anticancer agents, and also to the dimers themselves. Formula (I) in which : represents a single bond or a double bond.

  本发明涉及吡咯并[1,4]苯并二氮杂环己烷（PBD）二聚体的共轭物，包含它们的组合物以及它们的治疗用途，特别是作为抗癌剂。该发明还涉及制备这些共轭物的方法以及它们作为抗癌剂的用途，还涉及这些二聚体本身。公式（I）中：表示单键或双键。
• NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF
  申请人：BOUCHARD Hervé

  公开号：US20120225089A1

  公开（公告）日：2012-09-06

  Provided herein are cryptophycin conjugates and compositions containing them. Methods of making and using such compounds also are provided.

  本发明提供了隐藻素偶联物及其包含它们的组合物。还提供了制备和使用此类化合物的方法。
• Pentraxin I and Pentraxin receptor, inhibitors of said proteins and pharmaceutical compositions containing said compounds
  申请人：MERCK PATENT GmbH

  公开号：EP1101820A1

  公开（公告）日：2001-05-23

  Described are nucleic acid sequences encoding the human Pentraxin receptor and related proteins as well as a pharmaceutical composition comprising a therapeutically effective amount of (a) Pentraxin I or the human Pentraxin receptor, (b) a nonfunctional variant of the protein of (a), (c) an antibody to the protein of (a) or (b), (d) a nucleic acid sequence encoding the protein of (a) or (b), (e) an antisense RNA sequence characterized in that it is complementary to an Pentraxin I or human Pentraxin receptor mRNA and can selectively bind to said mRNA, said sequence being capable of inhibiting the synthesis of Pentraxin I or the human Pentraxin receptor, or (f) a ribozyme characterized in that it is complementary to an Pentraxin I or human Pentraxin receptor mRNA and can selectively bind to and cleave said mRNA, thus inhibiting the synthesis of Pentraxin I or the human Pentraxin receptor. Moreover, the use of the above compounds for treating neuronal disorders or providing a neuroprotective effect is described. The above compounds are also useful for detecting a disease associated with a neuronal disorder based on a deregulated expression of the above proteins or the presence of Pentraxin I/human Pentraxin receptor having no or at least reduced biological activity.

  描述了编码人类五胜肽受体和相关蛋白的核酸序列以及药物组合物，该药物组合物包含治疗有效量的(a) 五胜肽 I 或人类五胜肽受体，(b) (a)蛋白的无功能变体，(c) (a)或(b)蛋白的抗体，(d) 编码(a)或(b)蛋白的核酸序列、(e) 反义 RNA 序列，其特征在于该序列与五胜肽 I 或人类五胜肽受体 mRNA 互补，并可选择性地与所述 mRNA 结合，所述序列能够抑制五胜肽 I 或人类五胜肽受体的合成、或 (f) 核酶，其特征在于它与五胜肽 I 或人类五胜肽受体 mRNA 互补，并能选择性地与所述 mRNA 结合并裂解所述 mRNA，从而抑制五胜肽 I 或人类五胜肽受体的合成。此外，上述化合物还可用于治疗神经元紊乱或提供神经保护作用。上述化合物还可用于检测与神经元紊乱有关的疾病，检测的依据是上述蛋白的表达失调或存在无生物活性或至少生物活性降低的五胜肽 I/人五胜肽受体。
• Methods and systems for designing and/or characterizing soluble lipidated ligand agents
  申请人：Tufts Medical Center

  公开号：US10233219B2

  公开（公告）日：2019-03-19

  The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.

  本申请提供了制备由配体实体和脂质实体组成的可溶性脂质配体制剂的方法，在某些实施方案中，还提供了这些成分中每种成分的相关参数，从而能够适当选择成分，为任何给定的感兴趣的靶标组装活性制剂。